Abstract
There is an increasing number of evidence showing analgesic properties of the kynurenic acid (KYNA), and also some studies demonstrate that kynurenine might interact with the opioid system. Therefore in this study, for the first time we investigated the direct binding affinity of KYNA and its structural analog KYNA-1 towards mu, kappa and delta opioid receptor in competition binding experiments applying opioid receptor specific radioligands. The binding affinity measurements were performed in Chinese hamster ovary cell lines overexpressing the corresponding opioid receptor (mu and kappa opioid receptor were rat, delta opioid receptor were mouse sequence). Additionally we also examined the chronic effect of these compounds on mu, kappa and delta opioid receptor and also nociceptin peptide receptor mediated G-protein activity in [35S]GTPγS binding assays performed in mouse cortex and striatum membranes. Our results showed that KYNA and KYNA-1 had no affinity towards any of the three classic opioid receptors. On the other hand the compounds significantly decreased opioid and nociceptin receptor mediated G-protein activity or in some cases enhanced the potency of the activating ligand. Moreover, the alterations were receptor and brain region specific. Accordingly, we conclude that KYNA and KYNA-1 do not interact directly with the opioid receptors, but more likely alter the receptor functions intracellularly.
Keywords: [35S]GTPγS binding, G-protein, kynurenic acid, opioid receptors, radioligand binding.
CNS & Neurological Disorders - Drug Targets
Title:Inhibition of Opioid Receptor Mediated G-Protein Activity After Chronic Administration of Kynurenic Acid and its Derivative without Direct Binding to Opioid Receptors
Volume: 13 Issue: 9
Author(s): Ferenc Zador, Reza Samavati, Eszter Szlavicz, Bernadett Tuka, Engin Bojnik, Ferenc Fulop, Jozsef Toldi, Laszlo Vecsei and Anna Borsodi
Affiliation:
Keywords: [35S]GTPγS binding, G-protein, kynurenic acid, opioid receptors, radioligand binding.
Abstract: There is an increasing number of evidence showing analgesic properties of the kynurenic acid (KYNA), and also some studies demonstrate that kynurenine might interact with the opioid system. Therefore in this study, for the first time we investigated the direct binding affinity of KYNA and its structural analog KYNA-1 towards mu, kappa and delta opioid receptor in competition binding experiments applying opioid receptor specific radioligands. The binding affinity measurements were performed in Chinese hamster ovary cell lines overexpressing the corresponding opioid receptor (mu and kappa opioid receptor were rat, delta opioid receptor were mouse sequence). Additionally we also examined the chronic effect of these compounds on mu, kappa and delta opioid receptor and also nociceptin peptide receptor mediated G-protein activity in [35S]GTPγS binding assays performed in mouse cortex and striatum membranes. Our results showed that KYNA and KYNA-1 had no affinity towards any of the three classic opioid receptors. On the other hand the compounds significantly decreased opioid and nociceptin receptor mediated G-protein activity or in some cases enhanced the potency of the activating ligand. Moreover, the alterations were receptor and brain region specific. Accordingly, we conclude that KYNA and KYNA-1 do not interact directly with the opioid receptors, but more likely alter the receptor functions intracellularly.
Export Options
About this article
Cite this article as:
Zador Ferenc, Samavati Reza, Szlavicz Eszter, Tuka Bernadett, Bojnik Engin, Fulop Ferenc, Toldi Jozsef, Vecsei Laszlo and Borsodi Anna, Inhibition of Opioid Receptor Mediated G-Protein Activity After Chronic Administration of Kynurenic Acid and its Derivative without Direct Binding to Opioid Receptors, CNS & Neurological Disorders - Drug Targets 2014; 13 (9) . https://dx.doi.org/10.2174/1871527314666141205164114
DOI https://dx.doi.org/10.2174/1871527314666141205164114 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in the Development of Casein Kinase 1 Inhibitors
Current Medicinal Chemistry Meridianins: Marine-Derived Potent Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Current Medicinal Chemistry Chromosomal Aberrations and Genomic Instability Induced by Topoisomerase- Targeted Antitumour Drugs
Current Medicinal Chemistry - Anti-Cancer Agents Potential Therapeutic Approaches to Alzheimer’s Disease By Bioinformatics, Cheminformatics And Predicted Adme-Tox Tools
Current Neuropharmacology Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine Reactive Oxygen and Nitrogen Species in the Renal Ischemia/Reperfusion Injury
Current Pharmaceutical Design The Multiple Pharmaceutical Potential of Curcumin in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Chips for Brains
Current Genomics Improving the Targeting of Tubulin-Binding Agents: Lessons from Drug Resistance Studies
Current Pharmaceutical Design Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry The 1,4-Dihydropyridine Nucleus: A Pharmacophoric Template Part 1. Actions at Ion Channels
Mini-Reviews in Medicinal Chemistry Stimuli-Responsive Nanoparticles for siRNA Delivery
Current Pharmaceutical Design Gold Nanoparticle-Mediated High-Performance Enzyme-Linked Immunosorbent Assay for Detection of Tuberculosis ESAT-6 Protein
Micro and Nanosystems Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Astatine-211: Production and Availability
Current Radiopharmaceuticals P2Y Receptor Activation Affects the Proliferation and Differentiation of Glial and Neuronal Cells: A Focus on Rat C6 Glioma Cells
Current Neuropharmacology Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer
Current Pharmaceutical Design STAT3 as a Therapeutic Target for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry